The new patent entitled, ‘Solid Ganaxolone formulations and methods for the making and use thereof,’ describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of Ganaxolone and will provide coverage until the end of 2026.
Ganaxolone is being developed as a first in class treatment in epilepsy, posttraumatic stress disorder (PTSD) and Fragile-X syndrome (FXS).
Marinus Pharma R&D senior vice president Kenneth Shaw said neurosteroids like Ganaxolone have been difficult to formulate in the past because of differences in exposure that are dependent on the dose and amount of food in the stomach.
"Marinus’ discovery of a novel class of stabilizing agents has produced new nanoparticulate formulations of ganaxolone that appear to be superior to historical formulations in minimizing these differences," Shaw said.